Panic disorder

New England Journal of Medicine

Volumn 354, Issue 22, 2006, Pages

  Katon, Wayne J ^a  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPRAZOLAM; BENZODIAZEPINE; CITALOPRAM; CLONAZEPAM; DESIPRAMINE; ESCITALOPRAM; FLUOXETINE; FLUVOXAMINE; FLUVOXAMINE MALEATE; IMIPRAMINE; LEXIPRO; LORAZEPAM; MONOAMINE OXIDASE INHIBITOR; NORADRENALIN UPTAKE INHIBITOR; NORTRIPTYLINE; PAROXETINE; PLACEBO; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRICYCLIC ANTIDEPRESSANT AGENT; VENLAFAXINE; XANAX XR; BENZODIAZEPINE DERIVATIVE;

ANOREXIA; ANXIETY; ARTICLE; BEHAVIOR THERAPY; CLINICAL TRIAL; COGNITIVE DEFECT; COGNITIVE THERAPY; CONSTIPATION; DIZZINESS; DOSE RESPONSE; DRUG DEPENDENCE; DRUG HALF LIFE; DYSPNEA; EVALUATION; HEART PALPITATION; HUMAN; HYPERTENSION; INSOMNIA; META ANALYSIS; MOOD DISORDER; NAUSEA; NERVOUSNESS; ORTHOSTATIC HYPERTENSION; PANIC; PATIENT EDUCATION; PHYSICAL EXAMINATION; PRIORITY JOURNAL; RISK FACTOR; SCREENING; SEDATION; SEXUAL DYSFUNCTION; SIDE EFFECT; SLEEP DEPRIVATION; SOCIAL AVOIDANCE BEHAVIOR; SOMNOLENCE; SWEATING; SYSTEMATIC REVIEW; THORAX PAIN; TREMOR; URINARY HESITANCY; WEIGHT GAIN; XEROSTOMIA; ADULT; FEMALE; LIFE EVENT; PRACTICE GUIDELINE; REVIEW;

ADULT; ANTIDEPRESSIVE AGENTS, TRICYCLIC; BENZODIAZEPINES; COGNITIVE THERAPY; FEMALE; HUMANS; LIFE CHANGE EVENTS; PANIC DISORDER; PRACTICE GUIDELINES; RISK FACTORS; SEROTONIN UPTAKE INHIBITORS;

EID: 33744455686     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMcp052466     Document Type: Article

References (48)

1. Kessler RC, McGonagle KA, Zhao S, et al. Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States: results from the National Comorbidity Survey. Arch Gen Psychiatry 1994;51:8-19.
2. Spitzer RL, Kroenke K, Linzer M, et al. Health-related quality of life in primary care patients with mental disorders: results from the PRIME-MD 1000 Study. JAMA 1995;274:1511-7.
3. Leon AC, Olfson M, Broadhead WE, et al. Prevalence of mental disorders in primary care: implications for screening. Arch Fam Med 1995;4:857-61.
4. Roy-Byrne P, Katon W, Broadhead WE, et al. Subsyndromal ("mixed") anxiety - depression in primary care. J Gen Intern Med 1994;9:507-12.
5. Weissman MM, Bland RC, Canino GJ, et al. The cross-national epidemiology of panic disorder. Arch Gen Psychiatry 1997;54:305-9.
6. Diagnostic and statistical manual of mental disorders. 4th ed. rev.: DSM-IV-R. Washington, D.C.: American Psychiatric Association, 2000.
7. Merikangas KR, Zhang H, Avenevoli S, Acharyya S, Neuenschwander M, Angst J. Longitudinal trajectories of depression and anxiety in a prospective community study: the Zurich Cohort Study. Arch Gen Psychiatry 2003;60:993-1000.
8. Torgersen S. Genetic factors in anxiety disorders. Arch Gen Psychiatry 1983;40:1085-9.
9. Crowe RR, Noyes R, Pauls DL, Slymen D. A family study of panic disorder. Arch Gen Psychiatry 1983;40:1065-9.
10. Gorman JM, Kent JM, Sullivan GM, Coplan JD. Neuroanatomical hypothesis of panic disorder, revised. Am J Psychiatry 2000;157:493-505.
11. Roy-Byrne PP, Geraci M, Uhde TW. Life events and the onset of panic disorder. Am J Psychiatry 1986;143:1424-7.
12. Manfro GG, Otto MW, McArdle ET, Worthington JJ III, Rosenbaum JF, Pollack MH. Relationship of antecedent stressful life events to childhood and family history of anxiety and the course of panic disorder. J Affect Disord 1996;41:135-9.
13. Kendler KS, Bulik CM, Silberg J, Hettema JM, Myers J, Prescott CA. Childhood sexual abuse and adult psychiatric and substance use disorders in women: an epidemiological and cotwin control analysis. Arch Gen Psychiatry 2000;57:953-9.
14. Breslau N, Klein DF. Smoking and panic attacks: an epidemiologic investigation. Arch Gen Psychiatry 1999;56:1141-7.
15. Hettema JM, Prescott CA, Myers JM, Neale MC, Kendler KS. The structure of genetic and environmental risk factors for anxiety disorders in men and women. Arch Gen Psychiatry 2005;62:182-9.
16. Pilowsky DJ, Olfson M, Gameroff MJ, et al. Panic disorder and suicidal ideation in primary care. Depress Anxiety 2006;23:11-6.
17. Sareen J, Cox BJ, Afifi TO, et al. Anxiety disorders and risk for suicidal ideation and suicide attempts: a population-based longitudinal study of adults. Arch Gen Psychiatry 2005;62:1249-57.
18. Vickers K, McNally RJ. Panic disorder and suicide attempt in the National Comorbidity Survey. J Abnorm Psychol 2004;113:582-91.
19. Simon GE. Psychiatric disorder and functional somatic symptoms as predictors of health care use. Psychiatr Med 1992;10:49-59.
20. Walker EA, Gelfand AN, Gelfand MD, Katon WJ. Psychiatric diagnoses, sexual and physical victimization, and disability in patients with irritable bowel syndrome or inflammatory bowel disease. Psychol Med 1995;25:1259-67.
21. Katon W, Hall ML, Russo J, et al. Chest pain: relationship of psychiatric illness to coronary arteriographic results. Am J Med 1988;84:1-9.
22. Barsky AJ, Cleary PD, Coeytaux RR, Ruskin JN. Psychiatric disorders in medical outpatients complaining of palpitations. J Gen Intern Med 1994;9:306-13.
23. Weissman MM, Gross R, Fyer A, et al. Interstitial cystitis and panic disorder: a potential genetic syndrome. Arch Gen Psychiatry 2004;61:273-9.
24. Katon WJ, Buchwald DS, Simon GE, Russo JE, Mease PJ. Psychiatric illness in patients with chronic fatigue and those with rheumatoid arthritis. J Gen Intern Med 1991;6:277-85.
25. Katon WJ, Richardson L, Lozano P, McCauley E. The relationship of asthma and anxiety disorders. Psychosom Med 2004;66:349-55.
26. Margraf J, Ehlers A, Roth WT. Mitral valve prolapse and panic disorder: a review of their relationship. Psychosom Med 1988;50:93-113.
27. Fogarty J, Engel C, Russo J, Simon G, Katon W. Hypertension and pheochromocytoma testing: the association with anxiety disorders. Arch Fam Med 1994;3:55-60.
28. Stewart WF, Linet MS, Celentano DD. Migraine headaches and panic attacks. Psychosom Med 1989;51:559-69.
29. Keller MB, Hanks DL. Course and outcome in panic disorder. Prog Neuropsychopharmacol Biol Psychiatry 1993;17:551-70.
30. Bruce SE, Yonkers KA, Otto MW, et al. Inf luence of psychiatric comorbidity on recovery and recurrence in generalized anxiety disorder, social phobia, and panic disorder: a 12-year prospective study. Am J Psychiatry 2005;162:1179-87.
31. Katon W. Panic disorder in the medical setting. Washington, D.C.: National Institute of Mental Health, 1994. (NIH publication no. 94-3482.)
32. Stein MB, Roy-Byrne PP, McQuaid JR, et al. Development of a brief diagnostic screen for panic disorder in primary care. Psychosom Med 1999;61:359-64.
33. Spitzer RL, Kroenke K, Williams JB. Validation and utility of a self-report version of PRIME-MD: the PHQ primary care study: Primary Care Evaluation of Mental Disorders: Patient Health Questionnaire. JAMA 1999;282:1737-44.
34. Mitte K. A meta-analysis of the efficacy of psycho- and pharmacotherapy in panic disorder with and without agoraphobia. J Affect Disord 2005;88:27-45.
35. Bradwejn J, Ahokas A, Stein DJ, Salinas E, Emilien G, Whitaker T. Venlafaxine extended-release capsules in panic disorder: flexible-dose, double-blind, placebo-controlled study. Br J Psychiatry 2005;187:352-9.
36. Otto MW, Tuby KS, Gould RA, McLean RY, Pollack MH. An effect-size analysis of the relative efficacy and tolerability of serotonin selective reuptake inhibitors for panic disorder. Am J Psychiatry 2001;158:1989-92.
37. Gould RA, Otto MW, Pollack MH. A meta-analysis of treatment outcome for panic disorder. Clin Psychol Rev 1995;15:819-44.
38. Working Group on Panic Disorder. Practice guideline for the treatment of patients with panic disorder. Am J Psychiatry 1998;155:Suppl:1-34.
39. Susman J, Klee B. The role of high-potency benzodiazepines in the treatment of panic disorder. Prim Care Companion J Clin Psychiatry 2005;7:5-11.
40. Goddard AW, Brouette T, Almai A, Jetty P, Woods SW, Charney D. Early co-administration of clonazepam with sertraline for panic disorder. Arch Gen Psychiatry 2001;58:681-6.
41. Benzodiazepine dependence, toxicity and abuse: a task force report of the American Psychiatric Association. Washington, D.C.: American Psychiatric Association, 1990.
42. Landon TM, Barlow DH. Cognitive-behavioral treatment for panic disorder: current status. J Psychiatr Pract 2004;10:211-26.
43. Barlow DH, Gorman JM, Shear MK, Woods SW. Cognitive-behavioral therapy, imipramine, or their combination for panic disorder: a randomized controlled trial. JAMA 2000;283:2529-36. [Errata, JAMA 2000;284:2450,2597.]
44. Westen D, Morrison K. A multidimensional meta-analysis of treatments for depression, panic, and generalized anxiety disorders: an empirical examination of the status of empirically supported therapies. J Consult Clin Psychol 2001;69:875-99.
45. Yonkers KA, Bruce SE, Dyck IR, Keller MB. Chronicity, relapse, and illness - course of panic disorder, social phobia, and generalized anxiety disorder: findings in men and women from 8 years of follow-up. Depress Anxiety 2003;17:173-9.
46. Royal Australian and New Zealand College of Psychiatrists Clinical Practice Guidelines Team for Panic Disorder and Agoraphobia. Australian and New Zealand clinical practice guidelines for the treatment of panic disorder and agoraphobia. Aust N Z J Psychiatry 2003;37:641-56.
47. Katon WJ, Roy-Byrne P, Russo J, Cowley D. Cost-effectiveness and cost offset of a collaborative care intervention for primary care patients with panic disorder. Arch Gen Psychiatry 2002;59:1098-104.
48. Katon W, Russo J, Sherbourne C, et al. Incremental cost-effectiveness of a collaborative care intervention for panic disorder. Psychol Med 2006;36:353-63.